우미롤리무스

우미롤리무스
우미롤리무스 구조식 이미지
카스 번호:
851536-75-9
한글명:
우미롤리무스
동의어(한글):
우미롤리무스
상품명:
UMiroliMus
동의어(영문):
TRM986;TRM 986;TRM-986;BioliMus;UMiroliMus;BIOLIMUS A9;BioliMus A9 UMiroliMus;BioliMus, BioliMus A9, TRM 986;Rapamycin, 42-O-(2-ethoxyethyl)-
CBNumber:
CB22470849
분자식:
C55H87NO14
포뮬러 무게:
986.28
MOL 파일:
851536-75-9.mol

우미롤리무스 속성

끓는 점
991.0±75.0 °C(Predicted)
밀도
1.15±0.1 g/cm3(Predicted)
저장 조건
Store at -20°C
용해도
DMF: Soluble; DMSO: Soluble; Ethanol: Soluble; Methanol: Soluble
물리적 상태
고체
산도 계수 (pKa)
10.40±0.70(Predicted)
색상
White to light yellow

안전

우미롤리무스 C화학적 특성, 용도, 생산

개요

Coronary stents have dramatically improved the success rate of interventional cardiology in recent years, and stent implantation has become the standard of care in percutaneous coronary interventions. However, the long-term success of coronary stenting is hampered by a high rate of restenosis (i.e., recurrence of stenosis, or reblocking), which is caused by proliferation and migration of smooth muscle cells and production of extracellular matrix. The Biomatrix DES is a novel stent system combining a biodegradable PLA and the new anti-restenoic drug biolimus. Biolimus is a semi-synthetic analog of sirolimus wherein the hydroxyl moiety at position 42 is modified to an ethoxyethyl ether group. As with rapamycin, the mechanism of action of biolimus consists of forming a complex with intracellular 12-kDa FK506-binding protein (FKBP-12), which binds to the mammalian target of rapamycin (mTOR) and reversibly inhibits cell-cycle transition of proliferating smooth muscle cells.The antiproliferative potency of biolimus is similar to that of sirolimus; however, it is approximately 10-fold more lipophilic than sirolimus, which results in rapid absorption of the drug into fatty tissues and reduced systemic exposure. The Biomatrixs DES is produced by the absorption of a 1:1 combination of biolimus and PLA on a flexible stainless steel stent. The precision automated coating method used in the production of the stent ensures the PLA biolimus combination is applied solely to the abluminal surface of the stent. PLA is co-released with biolimus over 6 9 months, and biodegraded initially to lactic acid, and eventually to carbon dioxide and water.

용도

Umirolimus is a semi-synthetic macrocyclic lactone prepared from rapamycin by selective alkylation of the 42-hydroxy group, providing one of most hydrophobic tacrolimus analogues. Umirolimus has been targeted for use in stents and medical devices to suppress localised immunoreaction. Like all tacrolimus analogues, umirolimus binds to receptor protein, FKBP12. The complex then binds to mTOR and prevents it from interacting with target proteins. Umirolimus is extensively cited in the literature with over 70 citations.

우미롤리무스 준비 용품 및 원자재

원자재

준비 용품


우미롤리무스 공급 업체

글로벌( 30)공급 업체
공급자 전화 이메일 국가 제품 수 이점
Hubei Jusheng Technology Co.,Ltd.
18871490254
linda@hubeijusheng.com CHINA 28172 58
TargetMol Chemicals Inc.
+1-781-999-5354 +1-00000000000
marketing@targetmol.com United States 32072 58
BOC Sciences
16314854226; +16314854226
inquiry@bocsci.com United States 19741 58
Aladdin Scientific
+1-+1(833)-552-7181
sales@aladdinsci.com United States 52925 58
LGM Pharma 1-(800)-881-8210
inquiries@lgmpharma.com United States 2123 70
ChemStrong Scientific Co.,Ltd 0755-0755-66853366 13670046396
sales@chem-strong.com China 18043 56
Shanghai EFE Biological Technology Co., Ltd. 021-65675885 18964387627
info@efebio.com China 9806 58
Lynnchem 86-(0)29-85992781 17792393971
info@lynnchem.com China 4587 58
Novachemistry 44-20819178-90 02081917890
info@novachemistry.com United Kingdom 4381 58
Wuhan FengyaoTonghui Chemical Products Co., Ltd. 027-87466105 15377573527
2678564200@qq.com China 17987 58

Copyright 2019 © ChemicalBook. All rights reserved